Blood tests that can cover the entire liver are important, as NAFLD and NASH do not spread through the organ evenly. Despite being the current gold standard, a biopsy may miss advanced disease by taking tissue from the wrong area. (magicmine/Getty Images)

Though it is predicted to become a top cause of organ damage and liver transplants within this decade, treatments for nonalcoholic fatty liver disease, or NAFLD, have stalled for a simple reason: It can be hard to tell who has the condition and who does not.

Ref:https://www.fiercebiotech.com/medtech/siemens-blood-test-for-fatty-liver-disease-scores-de-novo-clearance-from-fda